Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer:: proof of mechanism

被引：558

作者：

Rowe, Christopher C. ^{[1
,2
]}

Ackerman, Uwe ^{[1
]}

Browne, William ^{[1
]}

Mulligan, Rachel ^{[1
]}

Pike, Kerryn L. ^{[1
]}

O'Keefe, Graeme ^{[1
]}

Tochon-Danguy, Henty ^{[1
]}

Chan, Gordon ^{[1
]}

Berlangieri, Salvatore U. ^{[1
]}

Jones, Gareth ^{[1
]}

Dickinson-Rowe, Kerryn L. ^{[1
]}

Kung, Hank P. ^{[3
]}

Zhang, Wei ^{[3
]}

Kung, Mei Ping ^{[3
]}

Skovronsky, Daniel ^{[4
]}

Dyrks, Thomas ^{[5
]}

Hall, Gerhard ^{[5
]}

Krause, Sabine ^{[5
]}

Friebe, Matthias ^{[5
]}

Lehman, Lutz ^{[5
]}

Lindemann, Stefanie ^{[5
]}

Dinkelborg, Ludger M. ^{[5
]}

Masters, Colin L. ^{[6
]}

Villemagne, Victor L. ^{[1
,6
]}

机构：

[1] Ctr PET, Austin Hlth, Dept Nucl Med, Heidelberg, Vic 3084, Australia

[2] Univ Melbourne, Dept Med, Parkville, Vic 3052, Australia

[3] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA

[4] AVID Radiopharmaceut, Philadelphia, PA USA

[5] Bayer Schering Pharma, Berlin, Germany

[6] Univ Melbourne, Mental Hlth Res Inst Victoria, Dept Pathol, Parkville, Vic 3052, Australia

来源：

LANCET NEUROLOGY | 2008年 / 7卷 / 02期

关键词：

D O I：

10.1016/S1474-4422(08)70001-2

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Background Amyloid-beta (AP) plaque formation is a hallmark of Alzheimer's disease (AD) and precedes the onset of dementia. A beta imaging should allow earlier diagnosis, but clinical application is hindered by the short decay half-life of current A beta-specific ligands. F-18-BAY94-9172 is an A beta ligand that, due to the half-life of F-18, is suitable for clinical use. We thus studied the effectiveness of this ligand in identifying patients with AD. Methods 15 patients with mild AD, 15 healthy elderly controls, and five individuals with frontotemporal lobar degeneration (FTLD) were studied. F-18-BAY94-9172 binding was quantified by use of the standardised uptake value ratio (SUVR), which was calculated for the neocortex by use of the cerebellum as reference region. SUVR images were visually rated as normal or AD. Findings F-18-BAY94-9172 binding matched the reported post-mortem distribution of A beta plaques. All AD patients showed widespread neocortical binding, which was greater in the precuneus/posterior cingulate and frontal cortex than in the lateral temporal and parietal cortex. There was relative sparing of sensorimotor, occipital, and medial temporal cortex. Healthy controls and FTLD patients showed only white-matter binding, although three controls and one FTLD patient had mild uptake in frontal and prectineus cortex. At 90-120 min after injection, higher neocortical SUVR was observed in AD patients (2.0 [SD 0-3]) than in healthy controls (1-3 [SD 0 - 21; p<0.0001) or FTLD patients (1.2 [SD 0.21; p=0-009). Visual interpretation was 100% sensitive and 90% specific for detection of AD. Interpretation F-18-BAY94-9172 PET discriminates between AD and FTLD or healthy controls and might facilitate integration of A beta imaging into clinical practice.

引用

页码：129 / 135

页数：7

共 33 条

[11] PET imaging of amyloid deposition in patients with mild cognitive impairment [J].

Forsberg, Anton ;

Engler, Henry ;

Almkvist, Ove ;

Blomquist, Gunnar ;

Hagman, Goran ;

Wall, Anders ;

Ringheim, Anna ;

Langstrom, Bengt ;

Nordberg, Agneta .

NEUROBIOLOGY OF AGING, 2008, 29 (10) :1456-1465

[12] Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease [J].

Kemppainen, N. M. ;

Aalto, S. ;

Wilson, I. A. ;

Nagren, K. ;

Helin, S. ;

Bruck, A. ;

Oikonen, V. ;

Kailajarvi, M. ;

Scheinin, M. ;

Viitanen, M. ;

Parkkola, R. ;

Rinne, J. O. .

NEUROLOGY, 2006, 67 (09) :1575-1580

[13] Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B [J].

Klunk, WE ;

Engler, H ;

Nordberg, A ;

Wang, YM ;

Blomqvist, G ;

Holt, DP ;

Bergström, M ;

Savitcheva, I ;

Huang, GF ;

Estrada, S ;

Ausén, B ;

Debnath, ML ;

Barletta, J ;

Price, JC ;

Sandell, J ;

Lopresti, BJ ;

Wall, A ;

Koivisto, P ;

Antoni, G ;

Mathis, CA ;

Långström, B .

ANNALS OF NEUROLOGY, 2004, 55 (03) :306-319

[14] PIB is a non-specific imaging marker of amyloid-beta (Aβ) peptide-related cerebral amyloidosis [J].

Lockhart, A. ;

Lamb, J. R. ;

Osredkar, T. ;

Sue, L. I. ;

Joyce, J. N. ;

Ye, L. ;

Libri, V. ;

Leppert, D. ;

Beach, T. G. .

BRAIN, 2007, 130 :2607-2615

[15]

Lopresti BJ, 2005, J NUCL MED, V46, P1959

[16] Clinical and pathological diagnosis of Frontotemporal Dementia - Report of the work group on Frontotemporal Dementia and Pick's disease [J].

McKhann, GM ;

Albert, MS ;

Grossman, M ;

Miller, B ;

Dickson, D ;

Trojanowski, JQ .

ARCHIVES OF NEUROLOGY, 2001, 58 (11) :1803-1809

[17] [11]PIB in a nondemented population -: Potential antecedent marker of Alzheimer disease [J].

Mintun, M. A. ;

LaRossa, G. N. ;

Sheline, Y. I. ;

Dence, C. S. ;

Lee, S. Y. ;

Mach, R. H. ;

Klunk, W. E. ;

Mathis, C. A. ;

DeKosky, S. T. ;

Morris, J. C. .

NEUROLOGY, 2006, 67 (03) :446-452

[18]

Mueller Susanne G, 2005, Alzheimers Dement, V1, P55, DOI 10.1016/j.jalz.2005.06.003

[19] Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease [J].

Ng, Steven ;

Villemagne, Victor L. ;

Berlangieri, Sam ;

Lee, Sze-Ting ;

Cherk, Martin ;

Gong, Sylvia J. ;

Ackermann, Uwe ;

Saunder, Tim ;

Tochon-Danguy, Henri ;

Jones, Gareth ;

Smith, Clare ;

O'Keefe, Graeme ;

Masters, Colin L. ;

Rowe, Christopher C. .

JOURNAL OF NUCLEAR MEDICINE, 2007, 48 (04) :547-552

[20] Evaluating atypical dementia syndromes using positron emission tomography with carbon 11-labeled Pittsburgh compound B [J].

Ng, Steven Y. ;

Villemagne, Victor L. ;

Masters, Colin L. ;

Rowe, Christopher C. .

ARCHIVES OF NEUROLOGY, 2007, 64 (08) :1140-1144

← 1 2 3 4 →